Balsari A - Search Results

1

HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N. Ménard S, et al. Among authors: balsari a. Clin Cancer Res. 2002 Feb;8(2):520-5. Clin Cancer Res. 2002. PMID: 11839672

2

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G. Moliterni A, et al. Among authors: balsari a. J Clin Oncol. 2003 Feb 1;21(3):458-62. doi: 10.1200/JCO.2003.04.021. J Clin Oncol. 2003. PMID: 12560435 Clinical Trial.

3

Role of proliferation in HER2 status predicted response to doxorubicin.

Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P, Ménard S. Campiglio M, et al. Among authors: balsari a. Int J Cancer. 2003 Jul 1;105(4):568-73. doi: 10.1002/ijc.11113. Int J Cancer. 2003. PMID: 12712452 Free article. Clinical Trial.

4

Role of HER2 in wound-induced breast carcinoma proliferation.

Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard S. Tagliabue E, et al. Among authors: balsari a. Lancet. 2003 Aug 16;362(9383):527-33. doi: 10.1016/S0140-6736(03)14112-8. Lancet. 2003. PMID: 12932384

5

Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness.

Tagliabue E, Agresti R, Casalini P, Mariani L, Carcangiu ML, Balsari A, Veronesi U, Ménard S. Tagliabue E, et al. Among authors: balsari a. Eur J Cancer. 2006 May;42(8):1057-61. doi: 10.1016/j.ejca.2005.12.021. Epub 2006 Apr 18. Eur J Cancer. 2006. PMID: 16624551 Clinical Trial.

6

Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact.

Casalini P, Carcangiu ML, Tammi R, Auvinen P, Kosma VM, Valagussa P, Greco M, Balsari A, Ménard S, Tagliabue E. Casalini P, et al. Among authors: balsari a. Clin Cancer Res. 2008 Jan 1;14(1):25-31. doi: 10.1158/1078-0432.CCR-07-0450. Clin Cancer Res. 2008. PMID: 18172248

7

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A. Merlo A, et al. Among authors: balsari a. J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255331

8

Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas.

Ménard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, Salvadori B, Colnaghi MI, Rilke F. Ménard S, et al. Among authors: balsari a. Clin Cancer Res. 1997 May;3(5):817-9. Clin Cancer Res. 1997. PMID: 9815754

9

Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle.

Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, Agresti R, Giovanazzi R, Alasio L, Rumio C, Cascinelli N, Colnaghi MI, Ménard S. Balsari A, et al. Am J Pathol. 1999 Nov;155(5):1543-7. doi: 10.1016/S0002-9440(10)65470-3. Am J Pathol. 1999. PMID: 10550311 Free PMC article.

10

Role of hormonal risk factors in HER2-positive breast carcinomas.

Balsari A, Casalini P, Bufalino R, Berrino F, Ménard S. Balsari A, et al. Br J Cancer. 2003 Apr 7;88(7):1032-4. doi: 10.1038/sj.bjc.6600844. Br J Cancer. 2003. PMID: 12671699 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

191 results

Search Page